Top

Published in:

01-06-2014 | Research Article

CYP1A1 and CYP2E1 genotypes and risk of esophageal squamous cell carcinoma in a high-incidence region, Kashmir

Authors: Gulzar Ahmad Bhat, Idrees Ayoub Shah, Muzamil Ashraf Makhdoomi, Beenish Iqbal, Rumaisa Rafiq, Sumaiya Nabi, Akbar Masood, Mohd Maqbool Lone, Nazir Ahmad Dar

Published in: Tumor Biology | Issue 6/2014

Abstract

The study analyzed the relationship between genetic polymorphisms of phase I xenobiotic metabolizing enzymes, cytochromes P450 (CYP) 1A1 and CYP2E1 and esophageal squamous cell carcinoma (ESCC) in Kashmir, India. The different genotypes of CYP1A1 and CYP2E1 were analyzed by polymerase chain reaction and restriction fragment length polymorphism in 526 ESCC cases and equal number of matched controls. Conditional logistic regression models were used to assess the association of various genotypes with ESCC, gene–gene, and gene–environment interactions. High risk of ESCC was found in participants who carried CYP1A1 Val/Val genotype (OR = 2.87; 95 % CI = 1.00–8.44) and the risk increased in such individuals when c1/c1 of CYP2E1 genotype was also present (OR = 5.68; 95 % CI = 1.09–29.52). Risk due to CYP1A1 Val/Val genotype was further enhanced (OR = 8.55; 95 % CI = 1.86–42.20) when the analysis was limited to ever smokers. Participants who carried CYP2E1 c1/c2 genotype showed an inverse relation (OR = 0.27; 95 % CI = 0.17–0.43) with ESCC. The inverse association of CYP2E1 c1/c2 genotype was retained when CYP1A1 Ile/Ile was also present (OR = 0.18; 95 % CI = 0.09–0.32), as well as when analysis was limited to ever smokers (OR = 0.45; 95 % CI = 0.23–0.90). Significant interaction was found between CYP1A1 (Val/Val) and CYP2E1 (c1/c1) genotypes (OR = 1.30; 95 % CI = 1.12–1.51; P = 0.001) and between CYP1A1 (Val/Val) and smoking (OR = 1.31; 95 % CI = 1.01–1.69; P = 0.043). The study suggests CYP1A1 Val/Val and CYP2E1 c1/c1 genotypes are significantly associated with ESCC risk.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.CrossRefPubMed

Wang LD, Zhou Q, Feng CW, Liu B, Qi YJ, Zhang YR, et al. Intervention and follow-up on human esophageal precancerous lesions in Henan, northern China, a high-incidence area for esophageal cancer. Gan To Kagaku Ryoho. 2002;29 Suppl 1:159–72.PubMed

Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(8):1893-907. doi:10.1158/1055-9965.epi-10-0437

Reed PI, Johnston BJ. The changing incidence of oesophageal cancer. Endoscopy. 1993;25(9):606–8. doi:10.1055/s-2007-1010414.CrossRefPubMed

Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21(4):322–7. doi:10.1111/j.1442-2050.2007.00776.x.CrossRefPubMed

Dar NA, Bhat GA, Shah IA, Iqbal B, Makhdoomi MA, Nisar I, et al. Hookah smoking, nass chewing, and oesophageal squamous cell carcinoma in Kashmir, India. Br J Cancer. 2012;107(9):1618–23. doi:10.1038/bjc.2012.449.PubMedCentralCrossRefPubMed

Siddiqi MA, Tricker AR, Kumar R, Fazili Z, Preussmann R. Dietary sources of N-nitrosamines in a high-risk area for oesophageal cancer—Kashmir, India. IARC Sci Publ. 1991;105:210–3.PubMed

Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer J Int du Cancer. 2005;113(3):456–63. doi:10.1002/ijc.20616.CrossRef

Turati F, Edefonti V, Bosetti C, Ferraroni M, Malvezzi M, Franceschi S, et al. Family history of cancer and the risk of cancer: a network of case-control studies. Ann Oncol. 2013. doi:10.1093/annonc/mdt280.

10.

Bye H, Prescott NJ, Matejcic M, Rose E, Lewis CM, Parker MI, et al. Population-specific genetic associations with oesophageal squamous cell carcinoma in South Africa. Carcinogenesis. 2011;32(12):1855–61. doi:10.1093/carcin/bgr211.PubMedCentralCrossRefPubMed

11.

Qin JM, Yang L, Chen B, Wang XM, Li F, Liao PH, et al. Interaction of methylenetetrahydrofolate reductase C677T, cytochrome P4502E1 polymorphism and environment factors in esophageal cancer in Kazakh population. World J Gastroenterol: WJG. 2008;14(45):6986–92.PubMedCentralCrossRefPubMed

12.

Shi Y, Luo GJ, Zhang L, Shi J, Zhang DQ, Chen JM, et al. Interaction between alcohol consumption and CYP 2C19 gene polymorphism in relation to oesophageal squamous cell carcinoma. PloS one. 2012;7(9):e43412. doi:10.1371/journal.pone.0043412.PubMedCentralCrossRefPubMed

13.

Tanaka F, Yamamoto K, Suzuki S, Inoue H, Tsurumaru M, Kajiyama Y, et al. Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut. 2010;59(11):1457–64. doi:10.1136/gut.2009.205724.CrossRefPubMed

14.

Boffetta P. Biomarkers in cancer epidemiology: an integrative approach. Carcinogenesis. 2010;31(1):121–6. doi:10.1093/carcin/bgp269.CrossRefPubMed

15.

Roshandel G, Semnani S, Malekzadeh R, Dawsey SM. Polycyclic aromatic hydrocarbons and esophageal squamous cell carcinoma. Arch Iran Med. 2012;15(11):713–22.PubMed

16.

Zhuo XG, Watanabe S. Factor analysis of digestive cancer mortality and food consumption in 65 Chinese counties. J Epidemiol. 1999;9(4):275–84.CrossRefPubMed

17.

Hakami R, Mohtadinia J, Etemadi A, Kamangar F, Nemati M, Pourshams A, et al. Dietary intake of benzo(a)pyrene and risk of esophageal cancer in north of Iran. Nutr Cancer. 2008;60:216–21.CrossRefPubMed

18.

Kamangar FSP, Pourshams A, Malekzadeh R, Boffetta P, Roth MJ, et al. High exposure to polycyclic aromatic hydrocarbons may contribute to high risk of esophageal cancer in northeastern Iran. Anticancer Res. 2005;25:425–8.PubMed

19.

Kawajiri K, Watanabe J, Hayashi S. Identification of allelic variants of the human CYP1A1 gene. Methods Enzymol. 1996;272:226–32.CrossRefPubMed

20.

Bergheim I, Wolfgarten E, Bollschweiler E, Holscher AH, Bode C, Parlesak A. Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma. World J Gastroenterol. 2007;13(7):997–1002.PubMedCentralCrossRefPubMed

21.

Rasool MT, Lone MM, Wani ML, Afroz F, Zaffar S, Mohib-ul HM. Cancer in Kashmir, India: burden and pattern of disease. J Cancer Res Ther. 2012;8(2):243–6. doi:10.4103/0973-1482.98978.CrossRefPubMed

22.

Khuroo MS, Zargar SA, Mahajan R, Banday MA. High incidence of oesophageal and gastric cancer in Kashmir in a population with special personal and dietary habits. Gut. 1992;33(1):11–5.PubMedCentralCrossRefPubMed

23.

Kumar R, Siddiqi M, Fazili Z, Wacker CD, Spiegelhalder B, Preussmann R. Effect of dietary nitrate on endogenous nitrosation of piperazine in humans. Cancer Lett. 1992;65(2):139–43.CrossRefPubMed

24.

Sambrook J, Russell D. Molecular cloning: a laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; 2001.

25.

Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 1996;56(21):4965–9.PubMed

26.

Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem. 1991;110(4):559–65.PubMed

27.

Godoy W, Albano RM, Moraes EG, Pinho PR, Nunes RA, Saito EH, et al. CYP2A6/2A7 and CYP2E1 expression in human oesophageal mucosa: regional and inter-individual variation in expression and relevance to nitrosamine metabolism. Carcinogenesis. 2002;23(4):611–6.CrossRefPubMed

28.

Murray GI, Shaw D, Weaver RJ, McKay JA, Ewen SW, Melvin WT, et al. Cytochrome P450 expression in oesophageal cancer. Gut. 1994;35(5):599–603.PubMedCentralCrossRefPubMed

29.

Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics. 1994;4(5):242–6.CrossRefPubMed

30.

Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett. 2001;165(2):171–7.CrossRefPubMed

31.

Rojas M, Cascorbi I, Alexandrov K, Kriek E, Auburtin G, Mayer L, et al. Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis. 2000;21(1):35–41.CrossRefPubMed

32.

Nakajima T, Wang RS, Nimura Y, Pin YM, He M, Vainio H, et al. Expression of cytochrome P450s and glutathione S-transferases in human esophagus with squamous-cell carcinomas. Carcinogenesis. 1996;17(7):1477–81.CrossRefPubMed

33.

Kiyohara C, Hirohata T, Inutsuka S. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res. 1996;87(1):18–24.CrossRefPubMed

34.

Gonzalez A, Ramirez V, Cuenca P, Sierra R. [Polymorphisms in detoxification genes CYP1A1, CYP2E1, GSTT1 and GSTM1 in gastric cancer susceptibility]. Rev Biol Trop. 2004;52(3):591–600.PubMed

35.

Kim RB, Yamazaki H, Chiba K, O'Shea D, Mimura M, Guengerich FP, et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther. 1996;279(1):4–11.PubMed

36.

Lucas D, Menez C, Girre C, Berthou F, Bodenez P, Joannet I, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics. 1995;5(5):298–304.CrossRefPubMed

37.

Leng W-D, Zeng X-T, Chen Y-J, Duan X-L, Niu Y-M, Long R-P, et al. Cytochrome P450 2E1 RsaI/PstI polymorphism and risk of esophageal cancer: a meta-analysis of 17 case-control studies. Exp Ther Med. 2012;4(5):938–48.PubMedCentralPubMed

38.

Wu MT, Lee JM, Wu DC, Ho CK, Wang YT, Lee YC, et al. Genetic polymorphisms of cytochrome P4501A1 and oesophageal squamous-cell carcinoma in Taiwan. Br J Cancer. 2002;87(5):529–32. doi:10.1038/sj.bjc.6600499.PubMedCentralCrossRefPubMed

39.

Liu R, Yin L-h, Yue-pu PU. Association of combined CYP2E1 gene polymorphism with the risk for esophageal squamous cell carcinoma in Huai’an population, China. Chin Med J. 2007;120(20):1797–802.PubMed

40.

Morita S, Yano M, Shiozaki H, Tsujinaka T, Ebisui C, Morimoto T, et al. CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer. 1997;71(2):192–5.CrossRefPubMed

41.

Danko IM, Chaschin NA. Association of CYP2E1 gene polymorphism with predisposition to cancer development. Exp Oncol. 2005;27(4):248–56.PubMed

42.

Garte S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis. 1998;19:1329–32.CrossRefPubMed

43.

Yuming NH, Yuan, Weidong L, Yongchu P, Ning G, Ning C. CYP2E1 Rsa I/Pst I polymorphism and esophageal cancer risk: a meta-analysis based on 1,088 cases and 2,238 controls. Med Oncol. 2011;28:182–7. doi:10.1007/s12032-010-9455-x.CrossRef

44.

Abnet CC, Wang Z, Song X, Hu N, Zhou FY, Freedman ND, et al. Genotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies. Human Mol Genet. 2012;21(9):2132–41. doi:10.1093/hmg/dds029.CrossRef

45.

Chen YZ, Cui XB, Hu JM, Zhang WJ, Li SG, Yang L, et al. Overexpression of PLCE1 in Kazakh esophageal squamous cell carcinoma: implications in cancer metastasis and aggressiveness. APMIS: Acta Pathol Microbiol Immunol Scand. 2013;121(10):908–18. doi:10.1111/apm.12095.CrossRef

46.

Duan F, Xie W, Cui L, Wang P, Song C, Qu H, et al. Novel functional variants locus in PLCE1 and susceptibility to esophageal squamous cell carcinoma: based on published genome-wide association studies in a central Chinese population. Cancer Epidemiol. 2013;37(5):647–52. doi:10.1016/j.canep.2013.04.009.CrossRefPubMed

47.

Malik MA, Upadhyay R, Mittal RD, Zargar SA, Mittal B. Association of xenobiotic metabolizing enzymes genetic polymorphisms with esophageal cancer in Kashmir Valley and influence of environmental factors. Nutr Cancer. 2010;62(6):734–42. doi:10.1080/01635581003605904.CrossRefPubMed

Title: CYP1A1 and CYP2E1 genotypes and risk of esophageal squamous cell carcinoma in a high-incidence region, Kashmir
Authors: Gulzar Ahmad Bhat
Idrees Ayoub Shah
Muzamil Ashraf Makhdoomi
Beenish Iqbal
Rumaisa Rafiq
Sumaiya Nabi
Akbar Masood
Mohd Maqbool Lone
Nazir Ahmad Dar
Publication date: 01-06-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1694-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Regulator of telomere elongation helicase 1 (RTEL1) rs6010620 polymorphism contribute to increased risk of glioma

Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?

Clinical significance of the stem cell gene Oct-4 in cervical cancer

NRP-1 expression in bladder cancer and its implications for tumor progression

Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker

Association between CLPTM1L-TERT rs401681 polymorphism and pancreatic cancer risk among Chinese Han population

Keynote webinar | Spotlight on antibody–drug conjugates in cancer